AZoNano on MSN40 分钟
Safety Assessment of Graphene-Based Materials: A Comprehensive Overview
As graphene materials gain traction, robust safety evaluations are essential to mitigate risks and support informed ...
PharmiWeb56 分钟
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...